Palisade Bio, Inc.

Equities

SNCA

US6963894026

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 20/05/2024 BST			5-day change	1st Jan Change
5.85 ^USD	-8.02%		-5.95%	-33.90%

05-10	Palisade Bio, Inc. announced that it has received $3.999943 million in funding	CI
05-07	Palisade Bio, Inc. Appoints Margery Fischbein to Its Board of Directors	CI

Palisade Bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023

August 10, 2023 at 10:04 pm

Palisade Bio, Inc. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported net loss was USD 3.39 million compared to USD 2.34 million a year ago. Basic loss per share from continuing operations was USD 7.95 compared to USD 86.55 a year ago. Diluted loss per share from continuing operations was USD 7.95 compared to USD 86.55 a year ago.
For the six months, net loss was USD 5.73 million compared to USD 6.55 million a year ago. Basic loss per share from continuing operations was USD 16.05 compared to USD 268.6499 a year ago. Diluted loss per share from continuing operations was USD 16.05 compared to USD 268.6499 a year ago.

Latest news about Palisade Bio, Inc.

Palisade Bio, Inc. announced that it has received $3.999943 million in funding	05-09	CI
Palisade Bio, Inc. Appoints Margery Fischbein to Its Board of Directors	05-07	CI
Wall Street Set to Open Lower Ahead of Fed Rate Decision; Private Employment Figures Top Forecasts	05-01	MT
Palisade Bio?s Lead Product Candidate, PALI-2108 Demonstrates Potent Anti-Inflammatory Effects in Ex-Vivo Study of Whole Blood Samples Challenged with Pro-Inflammatory Lipopolysaccharide	05-01	CI
Palisade Bio, Inc. announced that it expects to receive $3.999996 million in funding	04-30	CI
Palisade Bio Collaborating With Strand Life Sciences on Ulcerative Colitis Therapy	04-23	MT
Palisade Bio, Inc. Enters into Strategic Collaboration with Strand Life Sciences to Advance Precision Medicine Approach	04-23	CI
Sector Update: Health Care Stocks Edge Up Tuesday Afternoon	04-16	MT
Palisade Bio Shows Bioactivation of PALI-2108 in Study; Shares Rise	04-16	MT
Palisade Bio Successfully Demonstrates Bioactivation of PALI-2108 In Ex-Vivo Study of Normal Healthy and Ulcerative Colitis Patients? Stool	04-16	CI
North American Morning Briefing : Stocks Seen -2-	04-02	DJ
Palisade Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-26	CI
Palisade Bio, Inc. Announces Resignation of Mary Ann Gray as Member of the Board	03-06	CI
Palisade Bio Names Donald Williams as Chairman	02-13	MT
Palisade Bio, Inc. Announces Advisory Board Appointments	02-08	CI
Sector Update: Health Care Stocks Stronger Late Afternoon	01-29	MT
Sector Update: Health Care Stocks Advance Monday Afternoon	01-29	MT
Top Midday Gainers	01-29	MT
Palisade Bio's Shares Climb Following Preclinical Data on Ulcerative Colitis Drug Candidate	01-29	MT
Palisade Bio Says Giiant Pharma Receives Second Milestone Payment for PALI-2108 Development	12-28	MT
North American Morning Briefing : Stocks Futures -2-	11-20	DJ
Maxim Upgrades Palisade Bio to Buy From Hold, Price Target is $1.50	11-17	MT
North American Morning Briefing : Investors Weigh -2-	11-10	DJ
Palisade Bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
Palisade Bio, Inc. Announces the Appointment of Mitchell Jones, M.D., Ph.D., as Chief Medical Officer	11/09/23	CI

Chart Palisade Bio, Inc.

Duration

Period

More charts

Company Profile

Palisade Bio, Inc. is a biopharmaceutical company focused on developing novel therapeutics for serious chronic gastrointestinal diseases. It is engaged in advancing a PALI-2108 for the treatment of IBD, including UC and CD and are researching PALI-1908. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract. UC primarily affects the colon and the rectum. CD can affect any part of the gastrointestinal tract, from the mouth to the anus. PALI-2108 is a prodrug PDE4 inhibitor that operates through a mechanism within colon tissues, targeting the key enzyme phosphodiesterase-4 (PDE4). This enzyme is pivotal in cAMP hydrolysis, and by inhibiting PDE4, intracellular cAMP levels are elevated. This elevation leads to the downregulation of inflammatory cytokines and a reduction in the expression of cell adhesion molecules. By modulating these processes, PALI-2108 prevents the local infiltration and activation of inflammatory cells in the colon tissues.

Sector

Biotechnology & Medical Research

Calendar

05:30pm - Digestive Disease Week Conference

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

5.85 USD

Average target price

33.75 USD

Spread / Average Target

+476.92%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
PALISADE BIO, INC.	-33.90%	5.48M
MODERNA, INC.	+41.79%	54.04B
IQVIA HOLDINGS INC.	-0.56%	41.92B
LONZA GROUP AG	+49.62%	41.96B
CELLTRION, INC.	-7.20%	28.35B
ICON PUBLIC LIMITED COMPANY	+12.59%	26.35B
ALNYLAM PHARMACEUTICALS, INC.	-21.51%	19B
BIO-TECHNE CORPORATION	+6.92%	13B
UNITED THERAPEUTICS CORPORATION	+24.91%	12.19B
MEDPACE HOLDINGS, INC.	+29.60%	12.28B

Other Biotechnology & Medical Research